爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
ecomectin süstelahus
eco animal health europe limited - ivermektiin - süstelahus - 10mg 1ml 250ml 1tk; 10mg 1ml 50ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
intermec plus süstelahus
interchemie werken de adelaar eesti aktsiaselts - ivermektiin+klorsuloon - süstelahus - 10mg+100mg 1ml 50ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
intermec pour-on kriipsulahus
interchemie werken de adelaar eesti aktsiaselts - ivermektiin - kriipsulahus - 5mg 1ml 1000ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
intermec süstelahus
interchemie werken de adelaar eesti aktsiaselts - ivermektiin - süstelahus - 10mg 1ml 50ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
topimec f süstelahus
chanelle pharmaceuticals manufacturing limited - ivermektiin+klorsuloon - süstelahus - 10mg+100mg 1ml 500ml 1tk; 10mg+100mg 1ml 250ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
moxisolv la süstelahus
bimeda animal health limited - moksidektiin - süstelahus - 100mg 1ml 50ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
norador kriipsulahus
norbrook laboratories limited - doramektiin - kriipsulahus - 5mg 1ml 250ml 1tk; 5mg 1ml 20000ml 1tk; 5mg 1ml 5000ml 1tk; 5mg 1ml 2500ml 1tk; 5mg 1ml 10000ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
taurador kriipsulahus
norbrook laboratories limited - doramektiin - kriipsulahus - 5mg 1ml 5000ml 1tk; 5mg 1ml 2500ml 1tk; 5mg 1ml 1000ml 1tk; 5mg 1ml 10000ml 1tk; 5mg 1ml 250ml 1tk
爱沙尼亚 -
爱沙尼亚文 -
Ravimiamet
alphalben suukaudne suspensioon
alpha-vet kft. - albendasool - suukaudne suspensioon - 100mg 1ml 1000ml 1tk
欧盟 -
爱沙尼亚文 -
EMA (European Medicines Agency)
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.